Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inoviq Ltd ( (AU:IIQ) ) has provided an announcement.
INOVIQ Ltd has appointed Peter Gunzburg as a Non-Executive Director, effective October 20, 2025. Gunzburg, who has extensive experience as a public company director and investor, previously served as Chairman of BARD1 Life Sciences Limited, now INOVIQ Ltd. His appointment follows a request by Tian An Medicare Limited, a key investor in INOVIQ’s recent capital raise. Gunzburg’s return is seen as a strategic move to leverage his knowledge of the company’s technology and direction, particularly as INOVIQ advances its exosome-based diagnostics and therapeutics. The company is focused on achieving key development and commercial milestones, with its EXO-OC™ test poised to become a leading solution for ovarian cancer screening.
The most recent analyst rating on (AU:IIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
More about Inoviq Ltd
INOVIQ Ltd is a leader in exosome technology, focusing on next-generation diagnostics and therapeutics to transform cancer care. Their portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a preclinical CAR-exosome therapeutic program for solid tumors.
Average Trading Volume: 109,638
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$41.3M
See more insights into IIQ stock on TipRanks’ Stock Analysis page.